摘要
钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制药是一种新型降糖药,主要通过抑制肾小管SGLT-2抑制近端肾小管葡萄糖重吸收起到降糖作用,近来越来越多的大型临床试验表明SGLT-2抑制药有独立于降糖之外的肾脏保护作用。SGLT-2抑制药对糖尿病肾病的保护作用机制主要与改善肾脏血流动力学、改善缺氧、减轻炎症及某些代谢效应有关,该文综述SGLT-2抑制药对及其糖尿病肾病的保护作用机制。
The sodium-glucose cotransporter 2(SGLT-2)inhibitor is a new type of hypoglycemic agent.It plays a hypoglycemic role by inhibiting renal tubular SGLT-2 and inhibiting proximal tubular glucose reabsorption.Recently,more and more large clinical trials have shown that SGLT-2 inhibitors have renal protective effects independent of hypoglycemia.The protective mechanism of SGLT-2 inhibitors on diabetic kidney disease is mainly related to improving renal hemodynamics,improving hypoxia,reducing inflammation and some metabolic effects.This article reviews the SGLT-2 inhibitors and the protective mechanism of SGLT-2 inhibitors on diabetic kidney disease.
作者
余雅
杨定平
YU Ya;YANG Dingping(Department of Nephrology,Renmin Hospital of Wuhan University,Wuhan 430060,China)
出处
《医药导报》
CAS
北大核心
2020年第1期67-72,共6页
Herald of Medicine
基金
国家自然科学基金资助项目(81670631)
